Michael Frazis attempts to understand the FDA's decision to approve Biogen's aducanumab for Alzheimer's and the possible ramifications.
Information
- Show
- FrequencyUpdated Monthly
- Published10 June 2021 at 1:37 pm UTC
- Length13 min
- RatingClean
Michael Frazis attempts to understand the FDA's decision to approve Biogen's aducanumab for Alzheimer's and the possible ramifications.